

# Artificial intelligence in drug discovery and development: A comprehensive review

Punam Desai

Department of Pharmaceutical Sciences  
and Drug Research, College of Pharmacy,  
Pune, Maharashtra, India

## Correspondence:

Dr. Punam Desai, Department of  
Pharmaceutical Sciences and Drug  
Research, College of Pharmacy, Pune,  
Maharashtra, India.  
E-mail: punam.desai2211@gmail.com

**How to cite this article:** Desai P.  
Artificial intelligence in drug discovery  
and development: A comprehensive  
review. *Innov Pharm Planet*  
2023;11(4):72-76.

**Source of Support:** Nil.

**Conflicts of Interest:** None declared.

**Date of Submission:** 30-10-2023

**Date of Revision:** 05-11-2023

**Date of Acceptance:** 15-11-2023

## ABSTRACT

Artificial intelligence (AI) has significantly transformed drug discovery and development by accelerating processes, reducing costs, and enhancing precision. AI-driven methods, such as machine learning (ML), deep learning (DL), and natural language processing, are employed at various stages of the drug pipeline, including target identification, lead compound selection, and clinical trial optimization. AI's ability to analyze large datasets enables researchers to uncover disease mechanisms, design novel compounds, and predict key properties, such as toxicity and bioactivity. Generative AI models further enhance drug discovery by creating new molecules from scratch. In addition, AI contributes to optimizing clinical trials, predicting adverse events, and supporting drug repurposing efforts. While AI offers numerous advantages, challenges, such as data quality, regulatory concerns, and the integration of AI with existing systems must be addressed. The future of AI in drug development holds promise, particularly in areas, such as personalized medicine, where AI enables tailored treatment approaches. As AI technologies continue to evolve, their integration into pharmaceutical research will revolutionize drug discovery and improve patient outcomes.

**Keywords:** Artificial intelligence, clinical trials, deep learning, drug discovery, drug repurposing, generative models, machine learning, natural language processing, personalized medicine

## Role of Artificial Intelligence in Drug Discovery and Development

Artificial intelligence (AI) has revolutionized various aspects of the pharmaceutical industry, particularly in the areas of drug discovery and development. AI has the potential to accelerate the drug discovery process, reduce costs, and improve the success rate of bringing new drugs to market. AI-based methods can be applied at multiple stages of the drug discovery pipeline, including target identification, lead compound generation, and optimization.<sup>[1,2]</sup>

The traditional drug discovery process is often time-consuming, expensive, and fraught with failures. It is estimated that 86% of drug candidates developed between 2000 and 2015 did not meet their stated endpoints.<sup>[3]</sup> However, the recent advancements in AI

and machine learning (ML) have the potential to transform the drug discovery landscape. AI can help researchers better understand disease mechanisms, identify novel drug targets, and design more effective and safer drug candidates.<sup>[4]</sup>

Moreover, AI-based methods can reduce the need for physical testing of drug compounds by enabling high-fidelity molecular simulations and predicting key properties such as toxicity, bioactivity, and physicochemical characteristics. This can lead to significant cost savings and faster development timelines.

AI is being used to analyze large datasets, including omics data, phenotypic and expression data, disease associations, patents, publications, clinical trials, and research grants, to understand the biological mechanisms of diseases and identify novel drug targets.<sup>[4]</sup> AI systems, combined with tools, such as AlphaFold, can predict the 3D structures of targets and accelerate the design of appropriate drugs that bind to them.<sup>[4]</sup>

AI is being used to generate promising drug molecules entirely from scratch, bypassing the need for screening large libraries of candidate compounds. These systems, known as generative AI models, can create

### Access this article online

**Website:** <https://innovationaljournals.com/index.php/ip> **e-ISSN:** 2348-7275

**DOI:** 10.31690/ipplanet.2023.v011i04.020

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution NonCommercial Share Alike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

novel compounds with desired properties, such as high potency and selectivity.

AI is also being used to prioritize and rank promising lead compounds for further assessment, with AI approaches outperforming previous ranking techniques. In addition, AI is being used to generate synthesis pathways for producing hypothetical drug compounds and suggest modifications to make them easier to manufacture.<sup>[4]</sup>

AI is being used to design and optimize pre-clinical and clinical trials, reducing the time and cost associated with these stages. AI algorithms can help identify the most promising patient populations, optimize trial design, and predict clinical outcomes.<sup>[2]</sup>

While AI has shown great promise in drug discovery, there are still challenges that need to be addressed. These include the need for high-quality and diverse datasets, the interpretability of AI models, and the potential for bias and errors. In addition, regulatory agencies are working to develop guidelines for the use of AI in drug development to ensure the safety and efficacy of AI-generated drugs.<sup>[5]</sup>

Despite these challenges, the future of AI in drug discovery looks bright. As AI systems continue to improve and more data becomes available, the potential for AI to revolutionize the drug discovery process will only increase. The growing investment in AI-enabled drug discovery, with over \$5.2 billion raised in 2021 alone, is a testament to the excitement and potential of this field.<sup>[4]</sup>

## Key Stages of Drug Discovery and Development

The drug discovery and development process is a complex and multifaceted journey that typically spans several years and involves multiple stages. Each stage plays a crucial role in ensuring that a new drug is safe, effective, and commercially viable. Below, we outline the key stages of this process.

### Target Identification

Target identification is the first step in drug discovery, where researchers aim to identify biological molecules (often proteins) that are implicated in a disease. This stage involves:

#### Understanding disease mechanisms

Researchers study the underlying biology of diseases to determine which targets are most likely to yield effective treatments.

#### Data analysis

AI and ML tools analyze vast datasets, including genomic, proteomic, and metabolomic information, to identify potential drug targets.

#### Validation

Once potential targets are identified, they must be validated through experimental studies to ensure they play a significant role in the disease process.<sup>[6]</sup>

## Lead Compound Selection

After identifying and validating drug targets, the next step is to discover and select lead compounds that can interact with these targets. This stage includes:

### High-throughput screening

Large libraries of compounds are screened to identify those that exhibit desired biological activity against the target.

### Computational drug design

AI algorithms are employed to predict how different compounds will interact with the target, optimizing the selection process.

### Lead optimization

Selected lead compounds undergo modifications to improve their efficacy, selectivity, and pharmacokinetic properties, making them more suitable for further development.

## Pre-clinical Testing

Pre-clinical testing is conducted to evaluate the safety and biological activity of lead compounds before they are tested in humans. This stage involves:

### *In vitro* studies

Laboratory tests are performed to assess the biological activity and toxicity of the lead compounds using cell cultures.

### *In vivo* studies

Animal models are used to evaluate the pharmacokinetics (absorption, distribution, metabolism, and excretion) and toxicity of the compounds.

### Regulatory approval

Data from pre-clinical studies are compiled and submitted to regulatory agencies (e.g., the Food and Drug Administration) to gain approval for clinical trials.<sup>[7]</sup>

## Clinical Trials

Clinical trials are conducted in human subjects to assess the safety and efficacy of the drug. This stage is divided into three phases:

- Phase I: Focuses on safety, tolerability, and pharmacokinetics in a small group of healthy volunteers or patients.
- Phase II: Involves a larger group of patients to evaluate the drug's efficacy and further assess its safety.
- Phase III: Conducted on a larger population to confirm efficacy, monitor side effects, and compare the drug to standard or equivalent treatments. Successful completion of Phase III is crucial for regulatory approval.

## Post-Marketing Surveillance

Once a drug is approved and, on the market, post-marketing surveillance is essential to monitor its long-term safety and effectiveness. This stage includes:

### Pharmacovigilance

Continuous monitoring of adverse effects and long-term outcomes in the general population.

### Real-world evidence

Collecting data from actual usage of the drug to assess its performance in diverse patient populations and settings.

### Regulatory reporting

Manufacturers are required to report any new safety information to regulatory agencies, which may lead to label changes, additional warnings, or even withdrawal of the drug from the market if significant risks are identified.

## AI Techniques and Applications

### ML

ML is a subset of AI that involves training algorithms to learn from data and make predictions or decisions without being explicitly programmed. In drug discovery, ML is used for:

#### *Virtual screening*

Screening large compound libraries to identify potential lead compounds.

#### *Quantitative structure-activity relationship (QSAR) modeling*

QSAR models predict the biological activity of compounds based on their chemical structures.

#### *Toxicity prediction*

ML models predict the toxicity of compounds, helping to identify and eliminate potentially harmful drug candidates early in the development process.<sup>[6]</sup>

### DL

DL is a more advanced form of ML that uses artificial neural networks with multiple hidden layers. In drug discovery, DL is used for:

#### *Protein structure prediction*

DL models, such as AlphaFold can accurately predict the 3D structure of proteins, which is crucial for understanding their function and designing drugs that target them.

#### *Generative models*

DL models can generate novel drug-like molecules with desired properties, accelerating the lead discovery process.

#### *Image analysis*

DL models can analyze medical images, such as X-rays and magnetic resonance imaging scans, to aid in disease diagnosis and drug development.

### Natural language processing (NLP)

NLP is a field of AI that focuses on the interaction between computers and human language. In drug discovery, NLP is used for:

#### *Literature mining*

Extracting relevant information from scientific literature, patents, and clinical trial data to identify potential drug targets, side effects, and drug repurposing opportunities.

#### *Knowledge extraction*

Transforming unstructured data into structured knowledge that can be used for further analysis and decision-making.

#### *Question answering*

Developing AI assistants that can answer questions and provide insights based on the available data.

### Predictive modeling

Predictive modeling involves using AI and statistical techniques to forecast future outcomes based on historical data. In drug discovery, predictive modeling is used for.

#### *Clinical trial design*

Optimizing the design of clinical trials to improve their efficiency and success rates.

#### *Patient recruitment*

Identifying the most suitable patients for clinical trials based on their genetic profiles and medical histories.

#### *Adverse event prediction*

Predicting the likelihood of adverse events in clinical trials or post-marketing surveillance.

## Drug Repurposing through AI

### Drug repurposing is the process of identifying new uses for existing drugs. AI can accelerate drug repurposing by: Identifying novel indications

Analyzing large datasets to find connections between drugs and diseases that were previously unknown.

#### *Predicting drug-target interactions*

Using AI models to predict how existing drugs might interact with new targets, suggesting potential new uses.

#### *Optimizing clinical trials*

Designing more efficient clinical trials for drug repurposing candidates, as they have already passed safety tests.

## Advantages of AI in drug development

The integration of AI in drug development offers numerous advantages that enhance the efficiency and effectiveness of the entire process. Here are some of the key benefits:

### Speeding up the discovery process

AI significantly accelerates the drug discovery process by automating and optimizing various stages. ML algorithms can rapidly analyze vast datasets, including genomic and chemical information, to identify potential drug targets and candidates. This capability allows researchers to quickly sift through extensive libraries of compounds, leading to faster identification of promising leads. For instance, AI can reduce the time required for target identification and lead optimization, streamlining the overall drug development timeline and saving valuable resources.<sup>[1,3]</sup>

### Enhancing precision and reducing costs

AI enhances precision in drug development by enabling more accurate predictions of drug behavior and interactions. Through techniques such as QSAR modeling and molecular docking, AI can predict the pharmacological properties of compounds, including their efficacy, solubility, and toxicity. This predictive capability not only improves the quality of drug candidates but also reduces the likelihood of costly failures in later stages of development. Research indicates that the use of AI can potentially lower drug discovery costs by up to 70%, making it a financially attractive option for pharmaceutical companies.<sup>[8]</sup>

### AI-driven drug design

AI-driven drug design leverages advanced algorithms to create novel drug candidates with optimized properties. By using generative models and DL techniques, researchers can design new molecules that are more likely to succeed in clinical trials. AI can also facilitate drug repurposing by analyzing existing drugs for new therapeutic applications, thereby shortening development timelines and reducing costs associated with bringing a new drug to market. The ability to simulate and predict drug interactions and effects further enhances the design process, leading to the development of more effective and targeted therapies.<sup>[7]</sup>

## Challenges and limitations

While AI has the potential to revolutionize drug discovery and development, there are several challenges and limitations that need to be addressed:

### Data quality and availability

The success of AI in drug discovery is heavily dependent on the quality and availability of data. Many existing datasets are incomplete, biased, or of varying quality, which can lead to inaccurate predictions and suboptimal decision-making. In addition, the lack of standardized data formats and sharing protocols can hinder the effective integration of AI into the drug discovery process.

## Regulatory and ethical concerns

The use of AI in drug development raises regulatory and ethical concerns that need to be addressed. Regulatory agencies are still developing guidelines for the use of AI in this context, and there is a need for clear standards and validation processes to ensure the safety and efficacy of AI-generated drugs. Ethical considerations include the potential for bias in AI algorithms, the protection of patient privacy, and the transparency of decision-making processes.

### Integration of AI with existing processes

Integrating AI into the existing drug discovery and development workflows can be challenging. Many pharmaceutical companies have established processes and legacy systems that may not be compatible with AI technologies. Successful integration requires significant investments in infrastructure, training, and change management to ensure that AI is effectively leveraged throughout the drug discovery pipeline.

## Future Prospects

The future of AI in drug development is promising, with several emerging trends and collaborative efforts shaping the landscape. Here are some key areas of focus:

### Emerging AI trends in drug development

AI is expected to continue evolving, with several trends gaining traction:

#### *Advanced predictive modeling*

The use of sophisticated algorithms for predictive modeling will enhance the ability to forecast drug interactions, efficacy, and safety profiles, thereby improving the overall drug development process.<sup>[9]</sup>

#### *Generative AI in drug design*

Generative models will enable the creation of novel compounds with optimized properties, significantly speeding up the lead discovery process and potentially leading to more effective therapies.<sup>[8]</sup>

#### *Integration of AI with big data*

AI will increasingly leverage big data analytics to extract insights from vast datasets, including genomic, proteomic, and clinical data, facilitating more informed decision-making in drug development.

## Collaboration between AI and Pharmaceutical Companies

Collaboration between AI technology providers and pharmaceutical companies is expected to strengthen:

### Public-private partnerships

Collaborative efforts will enhance resource sharing, allowing pharmaceutical companies to access cutting-edge AI technologies and expertise, which can lead to more efficient drug discovery processes.<sup>[7]</sup>

## Cross-industry collaborations

Partnerships with tech companies specializing in AI and data analytics will enable pharmaceutical firms to integrate advanced AI tools into their workflows, enhancing their research capabilities and accelerating drug development timelines.

## Investment in AI startups

Pharmaceutical companies are increasingly investing in AI startups, recognizing the potential for innovative solutions that can streamline drug discovery and development processes.

## Role of AI in Personalized Medicine

AI is poised to play a crucial role in the advancement of personalized medicine: Patient.

### Stratification

AI algorithms will enable the identification of distinct patient populations based on genetic, phenotypic, and clinical data, allowing for tailored treatment approaches that improve efficacy and reduce adverse effects.<sup>[10]</sup>

### Predictive analytics for treatment responses

By analyzing real-world patient data, AI can predict how individual patients will respond to specific treatments, facilitating more personalized therapeutic strategies.

## Optimized drug formulations

AI will support the development of patient-specific drug formulations, taking into account individual characteristics such as age, weight, and genetic makeup, which can lead to improved treatment outcomes.

## Conclusion

AI has the potential to revolutionize drug discovery by utilizing ML, DL, NLP, predictive modeling, and drug repurposing to accelerate

the process, reduce costs, and increase success rates. As AI advances and more data become available, its impact on drug development will strengthen.

The benefits of AI include faster, more precise, and cost-effective drug development. As these technologies evolve, their integration will enhance efficiency and transform the pharmaceutical landscape. Despite challenges, AI is expected to play an increasingly important role in discovering new drugs and improving patient outcomes, especially with advancements in personalized medicine and collaborative efforts.

## References

1. Paul D, Sanap G, Shenoy S, Kalyane D, Kalia K, Tekade RK. Artificial intelligence in drug discovery and development. *Drug Discov Today* 2021;26:80-93.
2. Qureshi R, Irfan M, Gondal TM, Khan S, Wu J, Hadi MU, *et al.* AI in drug discovery and its clinical relevance. *Heliyon* 2023;9:e17575.
3. Arnold C. Inside the nascent industry of AI-designed drugs. *Nat Med* 2023;29:1292-5.
4. Tiwari PC, Pal R, Chaudhary MJ, Nath R. Artificial intelligence revolutionizing drug development: Exploring opportunities and challenges. *Drug Dev Res* 2023;84:1652-3.
5. US Food and Drug Administration. Artificial Intelligence and Machine Learning (AI/ML) in Drug Development. Maryland US: US Food and Drug Administration; 2023.
6. Jiménez-Luna J, Grisoni F, Weskamp N, Schneider G. Artificial intelligence in drug discovery: Recent advances and future perspectives. *Expert Opin Drug Discov* 2021;16:949-59.
7. Blanco-González A, Cabezon A, Seco-González A, Conde-Torres D, Antelo-Riveiro P, Piñeiro Á, *et al.* The role of AI in drug discovery: Challenges, opportunities, and strategies. *Pharmaceuticals (Basel)* 2023;16:891.
8. Mak KK, Wong YH, Pichika MR. Artificial intelligence in drug discovery and development. In: *Drug Discovery and Evaluation: Safety and Pharmacokinetic Assays*. Germany: Springer Nature; 2023. p. 1-38.
9. Mak KK, Pichika MR. Artificial intelligence in drug development: Present status and future prospects. *Drug Discov Today* 2019;24:773-80.
10. Sahu M, Gupta R, Ambasta RK, Kumar P. Artificial intelligence and machine learning in precision medicine: A paradigm shift in big data analysis. *Prog Mol Biol Transl Sci* 2022;190:57-100.